A key group of government advisers voted to expand the use of vaccines for a common respiratory illness, providing a boost to manufacturers whose sales fell sharply last year.

A CDC committee has voted to expand its respiratory syncytial virus vaccine recommendation to include all people aged 50 to 59 years.

CDC panel expands Pfizer and GSK RSV vaccine use to high-risk adults 50–59, building on earlier recommendations for older populations.